Solvay Pharmaceuticals
As of the edition of 20 October 2026, Solvay Pharmaceuticals runs 22 drugs, 14 of them marketed; it is on route A at 7 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Solvay Pharmaceuticals was acquired.
- Solvay Pharmaceuticals: acquired
Drugs by status
| Status | Count |
|---|---|
| Marketed | 14 |
| Went quiet | 3 |
| Stopped | 5 |
| Total | 22 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Hydrocortisone | none listed | 5 |
| Estradiol | Ends 2032 (patent) | 6 |
| Mesalamine | Ends 2027 (patent) | 12 |
| Lithium | none listed | 0 |
| Lithium carbonate | none listed | 3 |
| Lactulose | none listed | 0 |
| Ubidecarenone | none listed | 0 |
| Fluvoxamine | none listed | 3 |
| Dydrogesterone | none listed | 2 |
| Pancrelipase | Ended 2008 (computed from the first US licence) | 0 |
| Chenodiol | none listed | 1 |
| Benzthiazide | none listed | 1 |
| Lithium citrate anhydrous | none listed | 0 |
| Meprobamate | none listed | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 7 targets, route B at 2 targets.
All 9 rows on route A or B
In the product9 company-target rows on route A or B; 6 are not shown here, and no score is.
See all 9 targets where Solvay Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Heart and blood vessels: 8 trials led
- Mental health: 8 trials led
- Nervous system: 6 trials led